| Detected | Trial | Change |
|---|---|---|
| 2026-05-28 | NCT03798678 CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With… |
date change Primary completion pushed: 2023-11-08 -> 2026-09-11 |
| 2026-05-28 | NCT03798678 CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With… |
date change Completion pushed: 2023-11-08 -> 2026-09-11 |
| 2026-05-14 | NCT03798678 CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With… |
Trial terminated |
| 2026-05-14 | NCT03798678 CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With… |
critical why stopped: null → "Other - Drug supply issues and withdrawal of company support." |
| 2026-05-14 | NCT03798678 CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With… |
Enrollment reduced: 36 -> 19 participants |
| 2026-05-14 | NCT03798678 CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With… |
date change Primary completion moved earlier: 2026-06-30 -> 2023-11-08 |
| 2026-05-14 | NCT03798678 CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With… |
date change Completion moved earlier: 2026-06-30 -> 2023-11-08 |
| 2026-05-14 | NCT03528642 Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With… |
date change Primary completion pushed: 2026-05-08 -> 2026-09-11 |
| 2026-05-14 | NCT03528642 Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With… |
date change Completion pushed: 2026-05-08 -> 2026-09-11 |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 2 | |||
| NCT03872427 | Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor… | Advanced Malignant Solid Neoplasm | Active, Not Recruiting |
| Phase 1/2 | |||
| NCT03831932 | Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage… | Advanced Lung Non-Small Cell Carcinoma | Active, Not Recruiting |
| Phase 1 | |||
| NCT03528642 | Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With… | Astrocytoma, IDH-Mutant, Grade 2 | Active, Not Recruiting |
| NCT04250545 | Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in… | Leptomeningeal Neoplasm | Active, Not Recruiting |
| NCT03798678 | CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With… | Recurrent Multiple Myeloma | Active, Not Recruiting |